Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.

Researchers in the WashU Medicine Department of Ophthalmology & Visual Sciences have discovered key neuroprotective genes ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...

Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with advanced dry macular degeneration. The hair-thin patch replaces damaged retinal ...

Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company ...

Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting activated ...

Roughly 200 million people worldwide live with age-related macular degeneration, a condition that erodes central vision and, in its advanced dry form, has no approved treatment that can reverse the ...

Detailed price information for Bausch & Lomb Corp (BLCO-N) from The Globe and Mail including charting and trades.

The influencers, many of them aligned with the Make America Healthy Again Movement, say the medical establishment has unfairly demonized the compound. By Dani Blum There’s a compound that can reverse ...

New treatments for dry macular degeneration are helping slow vision loss, and researchers are testing therapies that may restore sight. Here’s what to know. Dry age-related macular degeneration is the ...